OncoKB New Data Release - April 30, 2026

6 views

Skip to first unread message

unread,

May 1, 2026, 4:27:45 PMMay 1

to oncok...@googlegroups.com

Data Release v7.1

April 30, 2026

What's New

We are now supporting germline variant annotation through the API! Please see our updated API documentation here. Important points:

Only HGVSg and HGVSc formats are currently supported for the germline API
New germline annotation endpoints are now available at “/api/v1/annotate/germline/…”. The existing “/api/v1/annotate/…” endpoints continue to serve somatic annotations.

We now have standard of care (Level 1 and 2) therapeutic implications for germline variants!

This release includes fifty Level 1 and seven Level 2 germline therapeutic associations across sixteen tumor types

Updated Actionable Genes page to support germline therapeutic implications
Updated FAQ page to answer common questions regarding our germline annotations and curation process
We recognize that our new registration requirement has raised questions, particularly in clinical settings. We are actively refining and clarifying our terms of use to ensure they are transparent and easy to understand, including what is freely available and what requires a license. In the meantime, research and clinical users will continue to have free access to the OncoKB website upon registration.

Updated Therapeutic Implications:

Level 1 - Germline: ATM, CHEK2, PALB2 and RAD51C Pathogenic Variants in prostate cancer based on FDA approvals of olaparib and talazoparib + enzalutamide (PMID: 32343890, 38049622)
Level 1 - Germline: BARD1, BRIP1, RAD51B and RAD51D Pathogenic Variants in prostate cancer based on FDA approval of olaparib (PMID: 32343890)
Level 1 - Germline: BRCA1 and BRCA2 Pathogenic Variants in pancreatic adenocarcinoma and acinar cell carcinoma of the pancreas based on FDA approval of olaparib (PMID: 31157963)

Level 2 sensitivity-associated evidence additionally included: Rucaparib (PMID: 33970687)

Level 1 - Germline: BRCA1 and BRCA2 Pathogenic Variants in peritoneal serous carcinoma, ovarian cancer and ovary/fallopian Tube based on FDA approvals of combination therapy olaparib + bevacizumab and monotherapies rucaparib, niraparib and olaparib (PMID: 40580808, 35658487, 37211045, 39284381, 27717299, 33743851, 30345884)

Level 2 sensitivity-associated evidence additionally included: Niraparib + Bevacizumab (PMID: 40602355)

Level 1 - Germline: BRCA1 and BRCA2 Pathogenic Variants in prostate cancer based on FDA approvals of combination therapies olaparib + abiraterone + prednisone, talazoparib + enzalutamide and niraparib + abiraterone acetate + prednisone and monotherapies olaparib and rucaparib (PMID: 37714168, 38049622, 32343890, 36795891, 36952634, 41057655)
Level 1 - Germline: FANCA, MLH1 and NBN Pathogenic Variants in prostate cancer based on FDA approval of talazoparib + enzalutamide (PMID: 32343890, 38049622)
Level 1 - Germline: NF1 Pathogenic Variants in neurofibroma based on FDA approvals of selumetinib and mirdametinib (PMID: 32187457, 40473450, 39514826)
Level 1 - Germline: PTCH1 Pathogenic Variants in basal cell carcinoma based on FDA approval of vismodegib (PMID: 22670903, 22670904)
Level 1 - Germline: RET Pathogenic Variants in medullary thyroid cancer based on FDA approval of selpercatinib (PMID: 37870969)
Level 1 - Germline: TSC1 and TSC2 Pathogenic Variants in encapsulated glioma based on FDA approval of everolimus (PMID: 23158522)
Level 1 - Germline: TSC1 and TSC2 Pathogenic Variants in renal angiomyolipoma based on FDA approval of everolimus (PMID: 23312829)

Level 2 sensitivity-associated evidence additionally included: Sirolimus (PMID: 18184959)

Level 1 - Germline: VHL Pathogenic Variants (excluding c.429C>T, c.571C>G and c.598C>T) in renal cell carcinoma, pancreatic neuroendocrine tumor and hemangioblastoma based on FDA approval of belzutifan (PMID: 34818478, 39284337)
Level 2 - Germline: PALB2 Pathogenic Variants in pancreatic cancer based on Pancreatic Adenocarcinoma NCCN Guideline inclusion of rucaparib (PMID: 23312829)